LEO Pharma / Astellas Pharma merger inquiry
The CMA investigated the anticipated acquisition by LEO Pharma A/S (LEO) of the portfolio of pharmaceutical dermatological products of Astellas Pharma Inc (Astellas).
|Phase 1 dates||Action|
|5 April 2016||Decision published|
|11 March 2016||Decision announced|
|22 January 2016||Launch of merger inquiry|
|22 January to 5 February 2016||Invitation to comment|
CMA clearance decision
11 March 2016: The CMA has cleared the acquisition by LEO Pharma A/S (LEO) of the portfolio of pharmaceutical dermatological products of Astellas Pharma Inc (Astellas). The full text of the decision is available below.
- Full text decision (5.4.16)
Launch of merger inquiry
22 January 2016: The CMA announced the launch of its merger inquiry by notice to the parties.
- Commencement of initial period notice (22.1.16)
Invitation to comment: Now closed
22 January 2016: The Competition and Markets Authority (CMA) is considering whether it is or may be the case that this transaction has resulted in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation has resulted, or may be expected to result, in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services.
Please send written representations about any competition or public interest to:
Competition and Markets Authority
37 Southampton Row
Published: 22 January 2016
Updated: 5 April 2016
Opened: 22 January 2016
Closed: 5 April 2016
- Full text of the decision published.
- Clearance decision announced.
- First published.